Skip to main content
Clinical Trials/ISRCTN37981524
ISRCTN37981524
Active, Not Recruiting
N/A

Safety and effectiveness clinical evaluation of injectable medical device hydragel A2 in the improvement of skin quality

ouna Aesthetics0 sites49 target enrollmentOctober 17, 2023

Overview

Phase
N/A
Intervention
Not specified
Conditions
Face skin quality
Sponsor
ouna Aesthetics
Enrollment
49
Status
Active, Not Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 17, 2023
End Date
August 16, 2024
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
ouna Aesthetics

Eligibility Criteria

Inclusion Criteria

  • Current inclusion criteria as of 12/02/2024:
  • 1\. Female or male
  • 2\. Any ethnicity
  • 3\. Skin phototype (according to Fitzpatrick scale) from II to V
  • 4\. Aged 30 to 60 years old
  • 5\. Seeking improvement of their skin quality
  • 6\. Have given consent for photographs for illustration purposes
  • 7\. Willing to abstain from other facial aesthetic procedures in the mid\-face through the entire study duration
  • 8\. In good general and mental health in the opinion of the investigator
  • 9\. Have the ability to read and fully understand the aims of the study and its conduct and have given their free, informed and expressed written consent

Exclusion Criteria

  • 1\. Any systemic disorder or skin disease that would in any way confound the interpretation of the study results
  • 2\. Medical/surgical/severe allergy/anaphylactic shock history that, in the opinion of the Investigator, could compromise the safety of the participant or affect the outcome of the study
  • 3\. Known risk of hypersensitivity to one of the components of the IP composition
  • 4\. Suffering from autoimmune disease
  • 5\. Cutaneous disorders, inflammation or infection (herpes, acne, etc.) at the treatment site or nearby
  • 6\. Medical history shows a sensitivity that could lead to a reaction to the treatment
  • 7\. Bleeding disorders or undergoing treatment with thrombolytics or anticoagulants
  • 8\. A tendency to form keloids, hypertrophic scars or any other healing disorders
  • 9\. Currently following a skin treatment
  • 10\. Pregnant or breastfeeding women or those considering a pregnancy during the study

Outcomes

Primary Outcomes

Not specified

Similar Trials